Tumor Biology

, Volume 36, Issue 12, pp 10003–10004 | Cite as

Erratum to: Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma

  • Yoshikazu Harada
  • Hiroto Izumi
  • Hirotsugu Noguchi
  • Akihiro Kuma
  • Yuichiro Kawatsu
  • Tomoko Kimura
  • Shohei Kitada
  • Hidetaka Uramoto
  • Ke-Yong Wang
  • Yasuyuki Sasaguri
  • Hiroshi Hijioka
  • Akihiko Miyawaki
  • Ryoichi Oya
  • Toshiyuki Nakayama
  • Kimitoshi Kohno
  • Sohsuke Yamada
Erratum

Erratum to: Tumor Biol.

DOI: 10.1007/s13277-015-3928-7

The original version of this article contained mistakes.

The corrected versions of the paragraph are given below in bold.

In the Introduction, The GalNAc-Ts, classified as 27 family members and, to date, consisting 20 members in human, show a tissue-specific expression and have different kinetic properties and acceptor substrate specificities [14].

In the Patient characteristics under Result, Based on the (TNM) classification of malignant tumors, 7th Edition, the ESOSCC patients had stage I (59/110; 53.6 %) and II (51/110; 46.4 %) disease, respectively.

In the Discussion, The biological aggressiveness of ESOSCC is reflected by the capability of carcinoma to recur, even in small OSCC lesions that are considered to have a relatively good prognosis [7]. Moreover, approximately 16–27 % of T1–2 OSCC cases potentially have occult metastases in regional lymph nodes [6, 7], which likely corresponds to the rate observed in the present study (29 of 110 patients; 26.4 %). Indeed, there are currently no reliable predictors of the progressive potential of ESOSCC. In this sense, the detection of the GalNAc-T3 expression patterns in both ESOSCC surgical specimens and preoperative biopsy samples may allow for improved patient selection of candidates for adjuvant/neoadjuvant systemic therapy and the need for neck dissection as well as prediction of the postoperative outcome, especially in the early phase. In particular, neck dissection is the most reliable treatment for addressing regional lymph node metastasis within the neck, although this method may also lead to complications, such as lymphatic leakage, injury of the facial nerve. However, the presence of a strong GalNAc-T3-positive expression on routine biopsy specimens significantly improves the ability to make appropriate preoperative decisions regarding the need for neck dissection and the subsequent impact on the quality of life of ESOSCC patients. Therefore, the clinical relevance of the GalNAc-T3 protein should be verified in the future in order to prevent unnecessary surgery and prolong the effects of beneficial surgical treatment for ESOSCC.

Collectively, our present data are in agreement with the findings of previous studies of several other epithelial cancers [11, 15–24].

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yoshikazu Harada
    • 1
    • 2
  • Hiroto Izumi
    • 3
  • Hirotsugu Noguchi
    • 1
  • Akihiro Kuma
    • 4
  • Yuichiro Kawatsu
    • 5
  • Tomoko Kimura
    • 5
  • Shohei Kitada
    • 1
    • 6
  • Hidetaka Uramoto
    • 7
  • Ke-Yong Wang
    • 1
    • 8
  • Yasuyuki Sasaguri
    • 1
    • 9
  • Hiroshi Hijioka
    • 10
  • Akihiko Miyawaki
    • 2
  • Ryoichi Oya
    • 2
  • Toshiyuki Nakayama
    • 1
  • Kimitoshi Kohno
    • 11
  • Sohsuke Yamada
    • 1
    • 12
    • 13
  1. 1.Department of Pathology, School of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
  2. 2.Department of Dentistry and Oral SurgeryUniversity Hospital of Occupational and Environmental HealthKitakyushuJapan
  3. 3.Department of Occupational PneumologyUniversity of Occupational and Environmental HealthKitakyushuJapan
  4. 4.Department of Second Internal MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
  5. 5.Department of Health Policy and Management, Institute of Industrial Ecological SciencesUniversity of Occupational and Environmental HealthKitakyushuJapan
  6. 6.Department of UrologyUniversity of Occupational and Environmental HealthKitakyushuJapan
  7. 7.Second Department of SurgeryUniversity of Occupational and Environmental HealthKitakyushuJapan
  8. 8.Shared-Use Research Center, School of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
  9. 9.Laboratory of PathologyFukuoka Wajiro HospitalFukuokaJapan
  10. 10.Department of Oral and Maxillofacial Surgery, Field of Oral and Maxillofacial Rehabilitation, Advanced Therapeutics Course, Graduate School of Medical and Dental SciencesKagoshima UniversityKagoshimaJapan
  11. 11.Asahi-Matsumoto HospitalKitakyushuJapan
  12. 12.Institute of PathologyMedical University of GrazGrazAustria
  13. 13.Institute of Molecular BiosciencesUniversity of GrazGrazAustria

Personalised recommendations